Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
Ramucirumab/paclitaxel shows an acceptable tolerability and numerically improved OS at 6 months. Due to the small number of patients, the current trial must be considered exploratory and more data are needed in this indication.
Authors
- Sylvie Lorenzen
- Claudia Pauligk
- Moritz Schiemer (ORCID: https://orcid.org/0000-0002-2082-4635)
- Magdalena K. Scheck (ORCID: https://orcid.org/0000-0003-3589-7535)
- Steffen Heeg (ORCID: https://orcid.org/0000-0003-3368-0703)
- Rolf Mahlberg
- S. Junge
- Disorn Sookthai
- Harald Schmalenberg
- Thomas J. Ettrich (ORCID: https://orcid.org/0000-0002-7654-2442)
- Salah‐Eddin Al‐Batran (ORCID: https://orcid.org/0000-0002-0279-8509)
- Thorsten Oliver Goetze (ORCID: https://orcid.org/0000-0002-8633-2748)
- Anne Treschl
- S. Heidel
- Stephan Kanzler
- Angelika Kestler
- Gunnar Hapke
- Michael Clemens
- Peter Thuss-Patience
Institutions
- Goethe University Frankfurt (DE)
- University Medical Center Freiburg (DE)
- TUM Klinikum (DE)
- Robert Bosch Hospital (DE)
- Städtisches Klinikum Dresden (DE)
- Leopoldina Krankenhaus Schweinfurt (DE)
- Klinikum Mutterhaus der Borromäerinnen (DE)
- Marienkrankenhaus Hamburg (DE)
- University Hospital Frankfurt (DE)
- Krankenhaus Nordwest (DE)
- Klinikum Saarbrücken (DE)
- University Hospital Ulm (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1159/000541174
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Eli Lilly and Company
- Lilly Deutschland